Phase 4 N=19 Use of Cidofovir for Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
Recurrent Respiratory Papillomatosis
Primary: Overall Response Rate Via Endoscopic Lesional Burden Score and/or RECIST — 21 Participants
Phase 2 N=9 M7824 in People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Respiratory Papillomatosis · Laryngeal Papilloma, Recurrent
Primary: Proportion of Participants With a Complete Response — 0; 0 proportion of participants
Phase 1 N=20 Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis
Primary: The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient…
Phase 2 N=13 Avelumab for People With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis · Juvenile Laryngeal Papilloma · Laryngeal Papilloma, Recurrent
Primary: Number of Patients With Laryngotracheal Recurrent Respiratory Papillomatosis (RPP) Who Achieve a Complete Response With Avelumab as Measured by Derkay Score Calculated…
N/A N=15 Human Papillomatosis Genotyping of Children in Thailand
Recurrent Laryngeal Papillomatosis · Human Papilloma Virus
Primary: Human Papillomavirus Genotypes — 6; 9 participants
Phase 2 N=41 Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis
Primary: Mean Percent Change in Papilloma Growth Rate at 12 Month Measurement Compared to Baseline — -5.4; -15.2 percent change in mean growth rate — p=0.57
Phase 2 N=32 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
N/A N=12 Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Human Papillomavirus (HPV)-Related Malignancies · Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies
Primary: Radiographic Responses, Determined by RECIST 1.1 Criteria — 5; 4; 3 Participants
Phase 2 N=61 Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus (RSV)
Primary: Time-Weighted Average Change in Viral Load From Day 1/Baseline Through Day 7 in Participants in the Full Analysis Set — -0.73; -0.90 log10 copies/mL — p=0.72
N/A N=26 Respiratory Impedance and Obliterative Bronchiolitis
Hematopoietic Stem Cell Transplantation · Obliterative Bronchiolitis
Primary: Airway Distensibility With Lung Inflation After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) — 0.07 1/cmH2O*s
N/A N=20 Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease
Nasal Polyps · Gastroesophageal Reflux
Primary: Presence of Reflux in Patients With Polyposis — 15 participants
Phase 2 N=40 Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis
Plastic Bronchitis · Protein-Losing Enteropathies · Healthy
Primary: Primary Endpoint: Number of Subjects That Develop New, Active Bleeding — 0 Participants
Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
N/A N=156 Typing of Human Papilloma Virus (HPV) From Female Genital Warts
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants
Phase 1 N=31 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants
N/A N=9 Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
HEAD & NECK Cancer
Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants
Phase 4 N=19 Hypoxic Pulmonary Vasoconstriction Pilot Study
Emphysema
Primary: Perfused Blood Volume Assessed for a Change in Lung Inflammation Pre and Post Dose Sildenafil Administration — 0.37; 0.42 coefficient of variation — p=<0.05
Phase 2 N=18 Inhaled GM-CSF Therapy of Autoimmune PAP
Autoimmune Pulmonary Alveolar Proteinosis
Primary: Time to Rescue WLL — 18; 30 Months — p=0.0078
Phase 2 N=189 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
Respiratory Syncytial Virus
Primary: Time-Weighted Average Change in Nasal Respiratory Syncytial Virus (RSV ) Viral Load From Baseline (Day 1) to Day 9 — -1.26; -0.91 log10 copies/mL — p=0.040
N/A N=49 FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates
Pulmonary Infiltrate New
Primary: Number of Patients With Positive Culture or Molecular Results After Brochoscopy — 40 participants
Phase 2 N=2 Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
N/A N=1,333 Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Pulmonary Arterial Hypertension
Primary: Prevalence of Respiratory Tract-Related Adverse Events of Interest — 52; 51; 16; 14 percentage of participants
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
N/A N=82 Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
N/A N=112 The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)
Human Papilloma Virus · Oropharyngeal Squamous Cell Carcinoma
Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants
Phase 2 N=21 RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness
Upper Respiratory Tract Infection · Lower Respiratory Tract Infection
Primary: Circulating RI-001 Titer — 9.24; 4.85; 1.42 Fold Change
Phase 2 N=60 Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
Respiratory Syncytial Virus Infection
Primary: Time-weighted Average Change in Nasal Respiratory Syncytial Viral (RSV) Load From Baseline to Day 9 — -1.00; -0.97 log10 copies/mL — p=0.94